Published in Infect Immun on February 01, 1997
Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. Genome Res (2009) 4.12
The alternative sigma factor, sigmaE, is critically important for the virulence of Salmonella typhimurium. Infect Immun (1999) 2.67
Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium. Infect Immun (2000) 1.88
Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. Elife (2013) 1.86
Searching for the elusive typhoid diagnostic. BMC Infect Dis (2010) 1.69
Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun (1999) 1.66
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 1.63
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun (2002) 1.47
Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun (2000) 1.44
Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun (1998) 1.42
How to become a top model: impact of animal experimentation on human Salmonella disease research. Infect Immun (2011) 1.40
Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect Immun (1998) 1.39
Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun (1998) 1.38
Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun (2002) 1.33
Salmonella typhimurium aroA, htrA, and aroD htrA mutants cause progressive infections in athymic (nu/nu) BALB/c mice. Infect Immun (1997) 1.32
In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun (2000) 1.32
Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun (2001) 1.27
Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine (2006) 1.27
Emergence of a globally dominant IncHI1 plasmid type associated with multiple drug resistant typhoid. PLoS Negl Trop Dis (2011) 1.26
A conserved acetyl esterase domain targets diverse bacteriophages to the Vi capsular receptor of Salmonella enterica serovar Typhi. J Bacteriol (2010) 1.24
Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol (2007) 1.23
Impact of homologous and non-homologous recombination in the genomic evolution of Escherichia coli. BMC Genomics (2012) 1.23
Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol (2009) 1.21
Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant. Infect Immun (1998) 1.20
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20
Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 1.17
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilin. J Bacteriol (2002) 1.16
Conserved DegP protease in gram-positive bacteria is essential for thermal and oxidative tolerance and full virulence in Streptococcus pyogenes. Infect Immun (2001) 1.15
Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. J Immunol (2011) 1.15
Salmonella Typhimurium-specific bacteriophage ΦSH19 and the origins of species specificity in the Vi01-like phage family. Virol J (2011) 1.14
Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect Immun (1999) 1.13
Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol (2012) 1.12
A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun (2008) 1.12
Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol (2008) 1.10
Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines. Infect Immun (2000) 1.05
Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses. Infect Immun (2001) 1.04
Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun (2001) 1.01
Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technology. Clin Vaccine Immunol (2010) 1.00
Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun (2000) 0.99
Role of sigma E-regulated genes in Escherichia coli uropathogenesis. Infect Immun (2006) 0.99
Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol (2004) 0.99
Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward. Front Immunol (2014) 0.99
Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA. Infect Immun (1999) 0.98
aro mutations in Salmonella enterica cause defects in cell wall and outer membrane integrity. J Bacteriol (2008) 0.93
Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes. Infect Immun (2002) 0.91
Comparison of abilities of Salmonella enterica serovar typhimurium aroA aroD and aroA htrA mutants to act as live vectors. Infect Immun (2000) 0.91
High-throughput comparison of gene fitness among related bacteria. BMC Genomics (2012) 0.90
Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun (2007) 0.89
Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human Vaccine production. Infect Immun (2002) 0.88
Evaluation of a simple blood culture amplification and antigen detection method for diagnosis of Salmonella enterica serovar typhi bacteremia. J Clin Microbiol (2012) 0.88
Live attenuated vaccines for invasive Salmonella infections. Vaccine (2015) 0.86
Salmonella enterica serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid. PLoS One (2011) 0.86
Typhoid fever & vaccine development: a partially answered question. Indian J Med Res (2012) 0.85
Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors. Infect Immun (2008) 0.85
Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines. Appl Environ Microbiol (2000) 0.83
Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infect Immun (2004) 0.82
Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA. J Infect Dis (2013) 0.82
Vaccines against gut pathogens. Gut (1999) 0.82
Characterization of the yehUT two-component regulatory system of Salmonella enterica Serovar Typhi and Typhimurium. PLoS One (2013) 0.81
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis (2009) 0.80
Genes Required for the Fitness of Salmonella enterica Serovar Typhimurium during Infection of Immunodeficient gp91-/- phox Mice. Infect Immun (2016) 0.79
Low-pH rescue of acid-sensitive Salmonella enterica Serovar Typhi Strains by a Rhamnose-regulated arginine decarboxylase system. J Bacteriol (2013) 0.79
A low gastric pH mouse model to evaluate live attenuated bacterial vaccines. PLoS One (2014) 0.79
Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice. Clin Vaccine Immunol (2013) 0.79
The Hd, Hj, and Hz66 flagella variants of Salmonella enterica serovar Typhi modify host responses and cellular interactions. Sci Rep (2015) 0.79
Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect Immun (2001) 0.78
The immune responses to bacterial antigens encountered in vivo at mucosal surfaces. Philos Trans R Soc Lond B Biol Sci (2000) 0.78
Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol (2007) 0.77
Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid. PLoS One (2015) 0.77
Expression library immunization: a road map for discovery of vaccines against infectious diseases. Infect Immun (2005) 0.76
Induced pluripotent stem cell derived macrophages as a cellular system to study salmonella and other pathogens. PLoS One (2015) 0.76
Stabilization of a plasmid coding for a heterologous antigen in Salmonella enterica serotype typhi vaccine strain CVD908-htrA by using site-specific recombination. Infect Immun (2006) 0.76
Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comp Immunol Microbiol Infect Dis (2012) 0.76
Animal Models for Salmonellosis: Applications in Vaccine Research. Clin Vaccine Immunol (2016) 0.75
Use of Ensure® nutrition shakes as an alternative formulation method for live recombinant Attenuated Salmonella Typhi vaccines. BMC Microbiol (2015) 0.75
Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. Ecosal Plus (2016) 0.75
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (1981) 19.90
Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis (1975) 4.51
The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol (1991) 3.52
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am J Vet Res (1984) 2.60
phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis (1996) 2.58
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: studies with an aromatic-dependent live S. typhimurium strain as a vaccine. Infect Immun (1985) 2.40
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun (1981) 2.15
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
An attenuated aroA Salmonella typhimurium vaccine elicits humoral and cellular immunity to cloned beta-galactosidase in mice. J Infect Dis (1987) 1.81
Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun (1984) 1.70
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine (1992) 1.69
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine (1992) 1.46
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis (1994) 1.43
Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest (1992) 1.39
Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908. Vaccine (1995) 1.38
Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect Immun (1992) 1.09
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature (2001) 15.44
Genome sequence of Yersinia pestis, the causative agent of plague. Nature (2001) 14.36
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med (1983) 11.15
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med (1995) 8.89
The transposon Tn1 as a probe for studying ColE1 structure and function. Mol Gen Genet (1977) 8.71
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis (1997) 6.64
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol (1998) 6.12
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
The great escape: structure and function of the autotransporter proteins. Trends Microbiol (1998) 4.72
A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. EMBO J (1998) 4.53
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
Developing information materials to present the findings of technology assessments to consumers. The experience of the NHS Centre for Reviews and Dissemination. Int J Technol Assess Health Care (1998) 4.49
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Virulence functions of autotransporter proteins. Infect Immun (2001) 4.07
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A plasmid-encoded type IV fimbrial gene of enteropathogenic Escherichia coli associated with localized adherence. Mol Microbiol (1992) 3.93
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Molecular switches--the ON and OFF of bacterial phase variation. Mol Microbiol (1999) 3.69
Analysis of sequences transposed by complementation of two classes of transposition-deficient mutants of Tn3. J Bacteriol (1978) 3.69
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Identification and characterization of TnphoA mutants of Salmonella that are unable to pass through a polarized MDCK epithelial cell monolayer. Mol Microbiol (1988) 3.59
The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol (1991) 3.52
Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens. J Clin Microbiol (1998) 3.50
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun (1988) 3.44
Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 3.43
Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis (1999) 3.38
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
Use of DNA probes and HEp-2 cell adherence assay to detect diarrheagenic Escherichia coli. J Infect Dis (1988) 3.19
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc Natl Acad Sci U S A (1989) 3.13
Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J Exp Med (2000) 3.12
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo. Infect Immun (1989) 3.00
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
Characterization of the C-terminal domains of intimin-like proteins of enteropathogenic and enterohemorrhagic Escherichia coli, Citrobacter freundii, and Hafnia alvei. Infect Immun (1994) 2.85
Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect Immun (1999) 2.78
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Salmonella: immune responses and vaccines. Vet J (2001) 2.68
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol (1981) 2.60
Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells. J Infect Dis (1998) 2.59
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Identification of sat, an autotransporter toxin produced by uropathogenic Escherichia coli. Mol Microbiol (2000) 2.53
Localization of a determinant for HEp-2 adherence by enteropathogenic Escherichia coli. Infect Immun (1986) 2.52
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Phylogenetic analysis of enteroaggregative and diffusely adherent Escherichia coli. Infect Immun (1999) 2.51
Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroaggregative Escherichia coli. Infect Immun (1997) 2.50
Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun (1999) 2.50
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Pet, an autotransporter enterotoxin from enteroaggregative Escherichia coli. Infect Immun (1998) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45